Influenza: Prospect for prevention and control

Kaohsiung Journal of Medical Sciences

Volumn 18, Issue 9, 2002, Pages 421-434

  Williams, Jason R ^a   Chen, Po Yen ^a   Cho, Cheng T ^a   Chin, Tom D Y ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Epidemic; Influenza; Influenza virus; Pandemic; Vaccine

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; DNA VACCINE; INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; PLASMID DNA; PLASMID VECTOR; RIMANTADINE; VIRUS RNA; ZANAMIVIR;

ANTIGENIC VARIATION; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG MECHANISM; DRUG TOLERABILITY; ELDERLY CARE; EPIDEMIC; HIGH RISK POPULATION; HUMAN; INCUBATION TIME; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MORBIDITY; MORTALITY; NONHUMAN; PREGNANCY; REVIEW; SIDE EFFECT; SWINE; VIRUS ISOLATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, DNA; VACCINES, INACTIVATED;

EID: 0036764383     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. rd Ed. New York: Churchill Livingstone; 1990.
2. Hampson AW. Surveillance for pandemic influenza. J Infect Dis 1997;176 (Suppl. 1): S8-13.
3. Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: A pattern of changing age distribution. J Infect Dis 1998;178:53-60.
4. Update: Influenza activity - United States and worldwide, May-September 2001. MMWR 2001;50:822-25.
5. Webster RG, Laver WG, Air GM, et al. Molecular mechanisms of variation in influenza viruses. Nature 1982;296:115-21.
6. Liu C, Eichelberger MC, Compans RW, et al. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995;69:1099-1106.
7. Webster RG. Predictions for future human influenza pandemics. J Infect Dis 1997;176 (Suppl 1):S14-9.
8. Guan Y, Peiris JA, Lipatove AS, et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci USA 2002;99:8950-5.
9. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999;354:916-7.
10. Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet 1996;348:901-2.
11. Webster RG. Influenza. In: Morse SS, ed. Emerging Viruses. New York: Oxford University Press; 1993:37-47.
12. Taubenberger JK, Reid AH, Krafft AE, et al. Initial genetic characterization of the 1918 "Spanish" influenza. Science 1997; 275:1793-6.
13. Reid AH, Fanning TG, Hultin JV, et al. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci USA 1999;96:1651-56.
14. Reid AH, Fanning TG, Janczewski TA, et al. Characterization of the 1918 "Spanish" influenza virus neuraminidase gene. Proc Natl Acad Sci USA 2000;97:6785-90.
15. Guan Y, Shortridge KF, Krauss S, et al. Emergence of avian H1N1 influenza viruses in pigs in China. J Virol 1996;70: 8041-6.
16. Mulder J, Masurel N. Pre-epidemic antibody against 1957 strain of Asian influenza in serum of older people living in the Netherlands. Lancet 1958;1:810-14.
17. Masurel N, Marine WM. Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man. Am J Epidemiol 1973; 97:44-9.
18. Fitch WM, Bush RM, Bender CA, et al. Long-term trends in the evolution of H(3) HA1 human influenza type A. Proc Natl Acad Sci USA 1997;94:7712-8.
19. Shu LL, Bean WJ, Webster RG. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol 1993;67:2723-9.
20. Kida H, Ito H, Yasuda J, et al. Potential for transmission of avian influenza viruses to pigs. J Gen Virol 1994;75:2183-8.
21. Ludwig S, Stitz L, Planz O, et al. European swine virus as a possible source for the next influenza pandemic? Virology 1995;212:555-61.
22. Wentworth DE, Thompson BL, Xu X, et al. An influenza A (H1N1) virus, closely related to swine influenza virus, responsible for a fatal case of human influenza. J Virol 1994;68:2051-8.
23. Top FH Jr., Russell PK. Swine influenza A at Fort Dix, New Jersey (January-February 1976). J Infect Dis 1977;136 (Suppl):S376-80.
24. Schoenbaum SC, McNeil BJ, Kavet J. The swine-influenza decision. N Engl J Med 1976;295:759-65.
25. Thompson RL, Sande MA, Wenzel RP, et al. Swine-influenza infections in civilians. N Engl J Med 1976;295:714-5.
26. Wells DL, Hopfensperger NA, Arden MW, et al. Swine influenza virus infections. JAMA 1991;265:478-81.
27. Bean WJ, Kawaoka Y, Wood JM, et al. Characterization of virulent and avirulent A / chicken / Pennsylvania / 83 influenza A viruses: Potential role of defective interfering RNAs in nature. J Virol 1985;54:151-60.
28. Horimoto T, Rivera E, Pearson J, et al. Origin of molecular changes associated with emergence of a highly pathogenic H5N2 influenza virus in Mexico. Virology 1995;213:223-30.
29. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-6.
30. Yuen KY, Chan PKS, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
31. Claas ECJ, Osterhaus A, Beek RV, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472-7.
32. Marwick C. Investigators present latest findings on Hong Kong 'Bird flu' to the FDA [Medical News & Perspectives]. JAMA 1998;279:643-4.
33. Chan PKS: Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002;34 (Suppl 2): S58-64.
34. Uyeki TM, Chong Y-H, Katz JM, et al. Lack of evidence of human-to-human transmission of Avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis 2002;8:154-9.
35. Cox NJ. Panel summary of international pandemic influenza plans. J Infect Dis 1997;176 (Suppl 1):S87-8.
36. Update: Influenza activity - United States and Worldwide, 2001-02 season, and composition of the 2002-03 influenza vaccine. MMWR 2002;51:503-6.
37. Shortridge KF. The next pandemic influenza virus? Lancet 1995;346:1210-2.
38. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47:1-25.
39. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-93.
40. Douglas RG Jr, Oates JA, Wood AJ. Prophylaxis and treatment of influenza. N Engl J Med 1990;322:443-50.
41. Update: Influenza activity - Worldwide and recommendations for influenza vaccine composition for the 1990-91 influenza season. MMWR 1990;39:293-6.
42. Update: Influenza activity - United States and worldwide, and the composition of the 1991-92 influenza vaccine. MMWR 1991;40:231-9.
43. Update: Influenza activity - United States and worldwide, and the composition of the 1992-93 influenza vaccine. MMWR 1992;41:315-23.
44. Update: Influenza activity - United States and worldwide, and the composition of the 1993-94 influenza vaccine. MMWR 1993;42:177-80.
45. Update: Influenza activity - United States and worldwide, 1993-94 season, and composition of the 1994-95 influenza vaccine. MMWR 1994;43:179-82.
46. Update: Influenza activity - United States and worldwide, 1994-95 season, and composition of the 1995-96 influenza vaccine. MMWR 1995;44:292-5.
47. Update: Influenza activity - United States and worldwide, 1995-96 season, and composition of the 1996-97 influenza vaccine. MMWR 1996;45:326-9.
48. Update: Influenza activity - United States and worldwide, 1996-97 season, and composition of the 1997-98 influenza vaccine. MMWR 1997;46:325-9.
49. Update: Influenza activity - United States and worldwide, 1997-98 season, and composition of the 1998-99 influenza vaccine. MMWR 1998;47:280-4.
50. Update: Influenza activity - United States and worldwide, 1998-99 season, and composition of the 1999-2000 influenza vaccine. MMWR 1999;48:374-8.
51. Update: Influenza activity - United States and worldwide, 1999-2000 season, and composition of the 2000-01 influenza vaccine. MMWR 2000;49:375-81.
52. Update: Influenza activity - United States, 2000-01 season. MMWR 2000;49:1085-7.
53. Glezen WP. Influenza. How to prepare for the 1997-1998 season. J Resp Dis 1997;18:721-35.
54. Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus infection in young children: A comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986;154:121-7.
55. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338:1405-12.
56. Johnson PR Jr., Feldman S, Thompson JM, et al. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985;17:325-35.
57. Gorse GJ, Belshe RB, Munn NJ. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol 1988; 26:911-8.
58. Swierkosz EM, Newman FK, Anderson EL, et al. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994;169:1121-4.
59. Fynan EF, Robinson HL, Webster RG. Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine. DNA Cell Biol 1993;12:785-9.
60. Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Ann Rev Immunol 1997;15:617-48.
61. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. DNA Cell Biol 1993; 12:777-83.
62. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
63. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine-enhanced protection against antigenic drift in influenza-virus. Nature Med 1995;1:583-7.
64. Palese P, Garcia-Sastre A. Influenza vaccines: Present and future. J Clin Invest 2002;110:9-13.
65. Talon J, Horvath CM, Polley R, et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci USA 2000;97:4309-14.
66. Kodihalli S, Kobasa D, Webster R. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000;18:2592-9.
67. Neirynck S, Derro T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med 1999;5:1157-63.
68. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998;26:1418-24.
69. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580-4.
70. Hayden FG, Osterhaus A, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337:874-80.
71. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35.
72. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283:1016-24.
73. Monto A, Moutl A, Sharp S. Effect of zanamivir on duration and resolution of influenza symptoms. Clin Ther 2000; 22:1294-305.
74. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001; 45:3403-8.
75. Kati WM, Montgomery D, Carrick R, et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus replication. Antimicrob Agents Chemother 2002; 47:1014-21.
76. Cox NJ, Fukuda K. Influenza. Emerg Infect Dis 1998;12:27-38.
77. Cox NJ. Panel summary of international pandemic influenza plans. J Infect Dis 1997;176 (Suppl 1):S87-8.
78. Laver G, Garman E. The origin and control of pandemic influenza. Science 2001;295:1776-7.